MedWatch

Foto: Mike Segar/Reuters/Ritzau Scanpix

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Biogen to apply for approval for antidepressant in 2022

After a short dialog with the authorities and its partner, Sage, Biogen is planning to start the application process for marketing authorization for its depression drug zuranolone in 2022. This is despite the fact that a recent study did not generate overwhelmingly convincing results.

Trial banner

Latest news

See all jobs